EP2459716A4 - Vecteurs à base adénovirale - Google Patents

Vecteurs à base adénovirale

Info

Publication number
EP2459716A4
EP2459716A4 EP10805122.8A EP10805122A EP2459716A4 EP 2459716 A4 EP2459716 A4 EP 2459716A4 EP 10805122 A EP10805122 A EP 10805122A EP 2459716 A4 EP2459716 A4 EP 2459716A4
Authority
EP
European Patent Office
Prior art keywords
adenoviral
based vectors
vectors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10805122.8A
Other languages
German (de)
English (en)
Other versions
EP2459716A1 (fr
EP2459716B1 (fr
Inventor
Timothy P Mayall
Jeff Alexander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PAXVAX Inc
Original Assignee
PAXVAX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PAXVAX Inc filed Critical PAXVAX Inc
Publication of EP2459716A1 publication Critical patent/EP2459716A1/fr
Publication of EP2459716A4 publication Critical patent/EP2459716A4/fr
Application granted granted Critical
Publication of EP2459716B1 publication Critical patent/EP2459716B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP10805122.8A 2009-07-31 2010-07-30 Vecteurs à base adénovirale Active EP2459716B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23061709P 2009-07-31 2009-07-31
PCT/US2010/043951 WO2011014794A1 (fr) 2009-07-31 2010-07-30 Vecteurs à base adénovirale

Publications (3)

Publication Number Publication Date
EP2459716A1 EP2459716A1 (fr) 2012-06-06
EP2459716A4 true EP2459716A4 (fr) 2013-06-19
EP2459716B1 EP2459716B1 (fr) 2016-08-17

Family

ID=43529721

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10805122.8A Active EP2459716B1 (fr) 2009-07-31 2010-07-30 Vecteurs à base adénovirale

Country Status (13)

Country Link
US (2) US8865182B2 (fr)
EP (1) EP2459716B1 (fr)
JP (1) JP5903045B2 (fr)
KR (1) KR20120052369A (fr)
CN (1) CN102549152B (fr)
AU (1) AU2010278797A1 (fr)
BR (1) BR112012008060A2 (fr)
CA (1) CA2769752A1 (fr)
ES (1) ES2603779T3 (fr)
IN (1) IN2012DN01827A (fr)
MX (1) MX2012001404A (fr)
RU (1) RU2012107702A (fr)
WO (1) WO2011014794A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN01827A (fr) 2009-07-31 2015-06-05 Paxvax Inc
WO2012024283A2 (fr) * 2010-08-16 2012-02-23 The Wistar Institute Of Anatomy And Biology Vaccins universels contre la grippe a
RU2013143149A (ru) * 2011-02-24 2015-03-27 Пэксвэкс, Инк. Составы, пригодные для вакцин, получаемых сушкой распылением
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
CN102775469B (zh) * 2011-05-12 2018-02-09 厦门大学 甲型流感病毒核衣壳蛋白的抗原表位及其用途
CN103732249A (zh) * 2011-05-23 2014-04-16 威斯特解剖及生物研究所 含有经修饰腺病毒载体的流感疫苗
US20130189303A1 (en) * 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
CA2850629C (fr) 2011-10-05 2024-05-21 Genvec, Inc. Vecteurs adenoviraux et procedes d'utilisation associes
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
EP2764014B1 (fr) 2011-10-05 2022-02-09 GenVec, Inc. Vecteurs adénoviraux et procédés d'utilisation
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
EP2855669B1 (fr) 2012-05-29 2018-10-10 GenVec, Inc. Vecteurs adénoviraux de sérotype 28 modifiés
US9676824B2 (en) * 2012-05-29 2017-06-13 Genvec, Inc. Herpes simplex virus vaccine
RU2507258C1 (ru) * 2012-08-21 2014-02-20 Общество с ограниченной ответственностью "НТфарма" Рекомбинантная псевдоаденовирусная частица на основе генома аденовируса человека 5 серотипа, для индукции специфического иммунитета к вирусу гриппа а субтипа н3n2 и способ ее использования
JP6576326B2 (ja) 2013-03-14 2019-09-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍溶解性アデノウイルス組成物
CN105579059B (zh) * 2013-09-03 2020-07-31 佐治亚科技研究公司 热稳定的疫苗配制物、工艺和包含疫苗配制物的微针
US9750801B2 (en) 2014-02-28 2017-09-05 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
US10617729B2 (en) 2014-12-24 2020-04-14 The Uab Research Foundation Multitargeting onocolytic adenovirus, methods of use, and methods of making
CA2988654A1 (fr) * 2015-06-12 2016-12-15 Glaxosmithkline Biologicals S.A. Polypeptides et polynucleotides d'adenovirus
US20190022209A1 (en) * 2016-01-15 2019-01-24 Etubics Corporation Methods and compositions for influenza vaccination
CN105567736B (zh) * 2016-02-03 2020-03-20 河南农业大学 缺失e3区复制完全型重组腺病毒4型载体系统的构建及其应用
AU2017223589B2 (en) 2016-02-23 2023-08-03 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
CA3013637A1 (fr) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Dosage a haut debit pour mesurer la cinetique de replication d'un adenovirus
CN107841513B (zh) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 基于M2e表位的广谱型流感疫苗
WO2018111767A1 (fr) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Adénovirus synthétiques ciblant une tumeur et leurs utilisations
JP2020515283A (ja) * 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
CN107686843A (zh) * 2017-09-11 2018-02-13 南方医科大学 一种基于腺病毒AdC6的表达载体及其构建方法
EA202090700A1 (ru) * 2017-10-16 2020-10-21 Глаксосмитклайн Байолоджикалс Са Компетентные по репликации аденовирусные векторы
CA3077630A1 (fr) * 2017-10-31 2019-05-09 Janssen Vaccines & Prevention B.V. Vecteurs d'adenovirus et leurs utilisations
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
CN109504802A (zh) * 2018-11-22 2019-03-22 李越希 一种检测11/55型人腺病毒的rpa方法、其专用引物和探针及用途
CN109504800A (zh) * 2018-11-22 2019-03-22 李越希 一种用于检测通用型人腺病毒的rpa方法、其专用引物和探针及用途
CN109504801A (zh) * 2018-11-22 2019-03-22 李越希 一种检测21型人腺病毒的rpa方法、其专用引物和探针及用途
CN111057685B (zh) * 2019-07-27 2022-03-18 中国人民解放军军事科学院军事医学研究院 一种复制型4型腺病毒载体重组马尔堡病毒病疫苗
CN111057716B (zh) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 用于包装重组人4型腺病毒的单质粒载体系统及其应用
CN113908265B (zh) * 2020-07-10 2024-03-15 上海市公共卫生临床中心 一种人4型、7型腺病毒减毒活疫苗及其应用
WO2023009264A1 (fr) * 2021-07-26 2023-02-02 Think Therapeutics, Inc. Compositions pour vaccins optimisés contre des peptides de la grippe
WO2023015276A1 (fr) * 2021-08-06 2023-02-09 Theravax, Inc. Vaccin à base de vecteur adénoviral pour virus émergents

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
WO1994017832A1 (fr) 1993-02-09 1994-08-18 The Scripps Research Institute Ciblage et transport de genes et d'agents antiviraux dans des cellules par l'adenovirus penton
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
CA2297786C (fr) 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Nouvel antigene immunoprotecteur contre la grippe a et son utilisation dans la vaccination
US7829329B2 (en) 1998-04-24 2010-11-09 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
JP2002512785A (ja) * 1998-04-24 2002-05-08 オニックス ファーマシューティカルズ，インコーポレイティド 疾患治療用のアデノウイルスベクター
KR20020013464A (ko) 1998-08-27 2002-02-20 추후제출 이종 유전자의 전달을 위한 표적화된 아데노바이러스 벡터
US6849446B2 (en) * 2000-05-31 2005-02-01 University Of Saskatchewan Modified bovine adenovirus having altered tropism
ES2327719T3 (es) 2001-01-18 2009-11-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Complejos de proteina oligomerica recombinante con potencial inmunogenico mejorado.
WO2003072703A2 (fr) 2002-02-05 2003-09-04 Cornell Research Foundation, Inc. Vecteur adenoviral a expression transgenique dependante de la replication
MXPA05013234A (es) * 2003-06-10 2006-03-09 Univ Saskatchewan Proteinas de capside de adenovirus quimericas.
US7144712B2 (en) 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CN1972958B (zh) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 应用腺病毒载体诱导免疫应答的方法
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US8926987B2 (en) 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
BRPI0518728A2 (pt) 2004-12-09 2008-12-02 Univ Pittsburgh vacinas para a resposta rÁpida À pandemia de gripe aviÁria
AU2006249877A1 (en) 2005-05-23 2006-11-30 Vaxin, Inc. Rapid production of adenovirus-free recombinant adenovirus vectors
WO2007050128A2 (fr) 2005-05-31 2007-05-03 Vectorlogics, Inc. Vecteurs adenoviraux proteges et leurs methodes d'utilisation
JP5097714B2 (ja) 2005-12-12 2012-12-12 カンジ，インコーポレイテッド Ｅ１領域内の発現カセットと不活性化されたｅ２ｂポリメラーゼを有するアデノウイルス発現ベクター
DK1988823T3 (en) 2006-02-09 2018-12-03 Genzyme Corp SLOW INTRAVENTRICULAR ADMINISTRATION
WO2007100908A2 (fr) 2006-02-28 2007-09-07 Vaxart, Inc Vecteurs anédoviraux chimériques
ATE455558T1 (de) 2006-04-28 2010-02-15 Univ Pennsylvania Modifiziertes adenovirus-hexon-protein und anwendungen davon
CA2657849A1 (fr) 2006-05-18 2008-05-08 Pharmexa Inc. Induction de reponses immunitaires au virus de la grippe en utilisant des compositions de polypeptides et d'acides nucleiques
EP2069376A4 (fr) 2006-07-21 2013-10-16 Pharmexa Inc Induction de réponses immunes cellulaires au virus de la grippe grâce à des compositions de peptides et d'acides nucléiques
CN101849012A (zh) * 2006-07-28 2010-09-29 联邦科学和工业研究组织 用于增加重组腺病毒载体的组织嗜性的方法和组合物
CN101358202B (zh) 2007-07-30 2011-02-09 中国农业科学院哈尔滨兽医研究所 重组犬2型腺病毒转移载体、其构建方法及应用
IN2012DN01827A (fr) 2009-07-31 2015-06-05 Paxvax Inc

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHANDA P K ET AL: "High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 175, no. 2, 1 April 1990 (1990-04-01), pages 535 - 547, XP023056038, ISSN: 0042-6822, [retrieved on 19900401], DOI: 10.1016/0042-6822(90)90438-W *
CHENGALVALA M V ET AL: "IMMUNOGENICITY OF HIGH EXPRESSION ADENOVIRUS-HEPATITIS B VIRUS RECOMBINANT VACCINES IN DOGS", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, vol. 75, 1 January 1994 (1994-01-01), pages 125 - 131, XP000653450, ISSN: 0022-1317 *
CHENGALVALA M V R ET AL: "Adenovirus vectors for gene expression", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 2, no. 5, 1 October 1991 (1991-10-01), pages 718 - 722, XP023601396, ISSN: 0958-1669, [retrieved on 19911001], DOI: 10.1016/0958-1669(91)90041-3 *
L.JEAN PATTERSON ET AL: "Insertion of HIV-1 Genes into Ad4[Delta]E3 Vector Abrogates Increased Pathogenesis in Cotton Rats Due to E3 Deletion", VIROLOGY, vol. 292, no. 1, 1 January 2002 (2002-01-01), pages 107 - 113, XP055061361, ISSN: 0042-6822, DOI: 10.1006/viro.2001.1248 *
MASON B B ET AL: "Adenovirus vaccine vectors expressing hepatitis B surface antigen: Importance of regulatory elements in the adenovirus major late intron", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 177, no. 2, 1 August 1990 (1990-08-01), pages 452 - 461, XP023059060, ISSN: 0042-6822, [retrieved on 19900801], DOI: 10.1016/0042-6822(90)90509-P *
S. C. JACOBS: "Characterization and manipulation of the human adenovirus 4 genome", JOURNAL OF GENERAL VIROLOGY, vol. 85, no. 11, 1 November 2004 (2004-11-01), pages 3361 - 3366, XP055061363, ISSN: 0022-1317, DOI: 10.1099/vir.0.80386-0 *
S. K. VERNON ET AL: "Ultrastructural characterization of human immunodeficiency virus type 1 Gag-containing particles assembled in a recombinant adenovirus vector system", JOURNAL OF GENERAL VIROLOGY, vol. 72, no. 6, 1 June 1991 (1991-06-01), pages 1243 - 1251, XP055061417, ISSN: 0022-1317, DOI: 10.1099/0022-1317-72-6-1243 *
See also references of WO2011014794A1 *
THERZAH M HORTON ET AL: "A Protein Serologically and Functionally Related to the Group C E3 14,700-Kilodalton Protein Is Found in Multiple Adenovirus Serotypes", JOURNAL OF VIROLOGY, vol. 64, no. 3, 1 March 1990 (1990-03-01), pages 1250 - 1255, XP055061364 *

Also Published As

Publication number Publication date
ES2603779T3 (es) 2017-03-01
MX2012001404A (es) 2012-06-01
BR112012008060A2 (pt) 2016-11-22
US8865182B2 (en) 2014-10-21
KR20120052369A (ko) 2012-05-23
CN102549152A (zh) 2012-07-04
EP2459716A1 (fr) 2012-06-06
JP5903045B2 (ja) 2016-04-13
JP2013501001A (ja) 2013-01-10
US20150086579A1 (en) 2015-03-26
CA2769752A1 (fr) 2011-02-03
RU2012107702A (ru) 2013-09-10
WO2011014794A1 (fr) 2011-02-03
US20110123564A1 (en) 2011-05-26
EP2459716B1 (fr) 2016-08-17
CN102549152B (zh) 2015-11-25
AU2010278797A1 (en) 2012-03-15
IN2012DN01827A (fr) 2015-06-05

Similar Documents

Publication Publication Date Title
EP2459716A4 (fr) Vecteurs à base adénovirale
EP2501753A4 (fr) Nanopapier résistant
IL215804A0 (en) Gene vector
EP2356718A4 (fr) Antennes conformées à un compteur optimisées
EP2396853A4 (fr) Antennes
PL2464939T3 (pl) Udoskonalony nośnik przedmiotu obrabianego
GB0914596D0 (en) Improved hatchcover
GB0820631D0 (en) Vectors
GB2470485B (en) Iron
HK1161321A1 (en) Iron
EP2447146A4 (fr) Planche de surf
GB0904677D0 (en) Novel case
GB0916844D0 (en) Novel case
GB0903156D0 (en) Remotely-Controllable object
GB2479079B (en) Iron
IL208602A0 (en) Mezuzah case
EP2388321A4 (fr) Nouveau vecteur d'expression
AU4240P (en) Tuckerbox xTriticosecale
GB0823425D0 (en) Vectors
GB0916388D0 (en) Improved fly-hook
TWM372836U (en) Case
GB0905223D0 (en) Case
GB0902215D0 (en) Sachet snipper
AU326628S (en) Surfboard
GB0906605D0 (en) Propelable surfboard

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

A4 Supplementary search report drawn up and despatched

Effective date: 20130517

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/70 20060101ALI20130513BHEP

Ipc: C12N 15/00 20060101AFI20130513BHEP

17Q First examination report despatched

Effective date: 20140612

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160322

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 821142

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160915

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010035680

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: VENI GMBH, CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20160817

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 821142

Country of ref document: AT

Kind code of ref document: T

Effective date: 20160817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161117

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161219

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161118

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2603779

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010035680

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161117

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20170518

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20170609

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20170613

Year of fee payment: 8

Ref country code: LU

Payment date: 20170710

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20170712

Year of fee payment: 8

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20170714

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180730

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20100730

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180730

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010035680

Country of ref document: DE

Representative=s name: WUESTHOFF & WUESTHOFF, PATENTANWAELTE PARTG MB, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602010035680

Country of ref document: DE

Owner name: EMERGENT TRAVEL HEALTH INC., REDWOOD CITY, US

Free format text: FORMER OWNER: PAXVAX, INC., SAN DIEGO, CALIF., US

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: EMERGENT TRAVEL HEALTH INC

Effective date: 20220420

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230609

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20230810

Year of fee payment: 14

Ref country code: CH

Payment date: 20230801

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240611

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240606

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240611

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240612

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240604

Year of fee payment: 15